# 2025年12月30日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 胆汁酸稳态与排泄的性别差异是男性与女性肝癌发病率差异的基础。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460563)
**期刊：** eLife
**PMID：** 41460563
**DOI：** 10.7554/eLife.96783

### 第一部分 原文与翻译

**英文原标题：** Sex differences in bile acid homeostasis and excretion underlie the disparity in liver cancer incidence between males and females.

> **英文摘要：**
> Hepatocellular carcinoma (HCC), the common liver cancer, exhibits higher incidence in males. Here, we report that mice lacking bile acid (BA) regulators, Farnesoid X Receptor (FXR also termed NR1H4) and Small Heterodimer Partner (SHP also termed NR0B2), recapitulate the sex difference in liver cancer risk. Since few therapeutic options are available, we focused on understanding the intrinsic protection afforded to female livers. Transcriptomic analysis in control and NR1H4 and NR0B2 double knockout livers identified female-specific changes in metabolism, including amino acids, lipids, and steroids. To assess translational relevance, we examined if transcriptomic signatures obtained from this murine HCC model correlate with survival outcomes for HCC patients. Gene signatures unique to the knockout females correspond with low-grade tumors and better survival. Ovariectomy blunts the metabolic changes and promotes liver tumorigenesis in females that, intriguingly, coincides with increased serum bile acid (BA) levels. Despite similar genetics, knockout male mice displayed higher serum BA concentrations, while female knockouts excreted more BAs. Decreasing enterohepatic BA recirculation using cholestyramine, an FDA-approved resin, dramatically reduced the liver cancer burden in male mice. Overall, we reveal that sex-specific BA metabolism leading to lower circulating BA concentration protects female livers from developing cancer. Thus, targeting BA excretion may be a promising therapeutic strategy against HCC.

> **中文摘要：**
> 肝细胞癌（HCC）是常见的肝癌类型，在男性中发病率更高。在此，我们报告缺乏胆汁酸（BA）调节因子——法尼醇X受体（FXR，又称NR1H4）和小异源二聚体伴侣（SHP，又称NR0B2）的小鼠，重现了肝癌风险的性别差异。由于现有的治疗选择有限，我们主要关注于理解女性肝脏所具有的内在保护机制。对对照组与NR1H4和NR0B2双基因敲除小鼠肝脏进行的转录组分析发现，女性特异性代谢变化涉及氨基酸、脂质和类固醇等代谢通路。为评估其转化意义，我们进一步探讨该小鼠HCC模型获得的转录组特征是否与人类HCC患者的生存结局相关。结果显示，敲除雌鼠特有的基因特征对应于低级别肿瘤和更好的生存预后。卵巢切除手术削弱了这些代谢变化并促进了雌性小鼠肝癌的发生，且有趣的是，这与血清胆汁酸水平的升高同时出现。尽管其遗传背景相同，敲除雄鼠表现出更高的血清胆汁酸浓度，而敲除雌鼠则排泄出更多胆汁酸。通过使用经FDA批准的树脂药物考来烯胺降低肠肝循环中的胆汁酸再循环，显著减少了雄性小鼠的肝癌负担。总体而言，我们揭示出性别特异性的胆汁酸代谢可通过降低循环胆汁酸浓度保护雌性肝脏免于癌变。因此，靶向胆汁酸排泄可能是治疗HCC的一种有前景的策略。

### 第二部分 AI 大师评价

该研究聚焦于肝癌性别差异的代谢基础，利用FXR与SHP双敲除小鼠模型揭示了胆汁酸稳态与排泄差异是关键驱动力。作者通过转录组学与代谢分析发现雌性肝脏具有特异性保护机制，并在临床数据中验证了转录特征与患者生存的相关性。实验性卵巢切除及考来烯胺干预进一步验证胆汁酸循环对肝癌风险的调控作用。研究创新性地提出了通过调节胆汁酸排泄改善肝癌预后的潜在治疗方向，但仍需在人体中进一步验证机制及安全性。

---

## 2. 前列腺炎综述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460524)
**期刊：** JAMA
**PMID：** 41460524
**DOI：** 10.1001/jama.2025.21097

### 第一部分 原文与翻译

**英文原标题：** Review of Prostatitis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献为关于前列腺炎的综述性研究，旨在整合和评述当前对前列腺炎的临床认识、诊断与治疗进展。虽然原文暂无摘要，但标题显示该研究可能系统总结了疾病的病理机制、分类、诊治策略及未解问题。此类综述对指导临床实践和未来研究方向具有重要价值，但具体创新点和方法细节需参阅正文确认。

---

## 3. 过度清扫非转移性肿瘤引流淋巴结会损害复发性胆道癌免疫治疗的疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460246)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41460246
**DOI：** 10.1158/1078-0432.CCR-25-3296

### 第一部分 原文与翻译

**英文原标题：** Excessive dissection of non-metastatic tumor-draining lymph nodes impairs immunotherapy efficacy in recurrent biliary tract cancer.

> **英文摘要：**
> PURPOSE: Non-metastatic tumor-draining lymph nodes (TDLNs-) are central to initiating and sustaining antitumor immunity. The impact of their surgical removal on immunotherapy efficacy in recurrent biliary tract cancer (BTC) remains unclear. We investigated the effect of TDLNs- dissection extent on treatment outcomes in this population.
> 
> METHODS: This real-world study retrospectively analyzed clinical and survival data from 101 recurrent BTC patients who received immunotherapy across five Chinese hospitals (2018-2023). Patients were stratified by extent of TDLNs- dissection (≤6 vs >6). Multiplex immunofluorescence (mIF) analysis of lymph node immune microenvironments was performed in a representative subset of patients (n=20) from Sun Yat-sen Memorial Hospital.
> 
> RESULTS: Patients with ≤6 TDLNs- dissected (n=59) achieved significantly longer progression-free survival (PFS) than those with >6 dissected (n=42) (HR, 0.48; 95% CI, 0.31-0.73; p = 0.001), although there was no statistically difference in overall survival. The mIF staining analysis revealed that TDLNs- contained higher densities of TCF-1+PD-1-CD8+ tumor-specific memory T cells and CD11c+ conventional dendritic cells, and lower proportions of FOXP3+CD4+ regulatory T cells and TCF-1-PD-1+CD69+CD8+ terminally exhausted T cells compared with metastatic TDLNs (TDLNs+). Among immunotherapy responders, TDLNs- exhibited greater TCF-1+PD-1-CD8+ T cell and CD11c+ cell densities than those in non-responders. Importantly, a higher proportion of TCF-1+PD-1-CD8+ T cells in TDLNs- correlated with improved PFS, whereas extensive dissection of TDLNs- diminished this benefit.
> 
> CONCLUSION: Excessive removal of TDLNs- compromises the efficacy of immunotherapy in recurrent BTC. A selective lymphadenectomy approach that prioritizes clearance of TDLNs+ while preserving TDLNs- may optimize outcomes for patients receiving postoperative immunotherapy.

> **中文摘要：**
> 研究目的：非转移性肿瘤引流淋巴结（TDLNs-）在抗肿瘤免疫的启动与维持中起核心作用。其外科切除对复发性胆道癌（BTC）免疫治疗疗效的影响尚不明确。本研究探讨了不同范围TDLNs-清扫对该人群治疗结局的影响。
> 
> 研究方法：这项真实世界研究回顾性分析了2018至2023年期间在中国五家医院接受免疫治疗的101例复发性BTC患者的临床与生存数据。根据TDLNs-清扫范围分组（≤6个与>6个）。同时，在中山大学孙逸仙纪念医院中选取20例代表性患者，通过多重免疫荧光（mIF）分析淋巴结免疫微环境。
> 
> 研究结果：清扫≤6个TDLNs-的患者（n=59）较清扫>6个者（n=42）的无进展生存期（PFS）显著延长（HR=0.48；95% CI：0.31-0.73；p=0.001），但总体生存期差异无统计学意义。mIF染色分析显示，与转移性引流淋巴结（TDLNs+）相比，TDLNs-中肿瘤特异性记忆T细胞（TCF-1+PD-1-CD8+）和CD11c+常规树突状细胞密度更高，而调节性T细胞（FOXP3+CD4+）及终末衰竭T细胞（TCF-1-PD-1+CD69+CD8+）比例更低。在免疫治疗应答者中，TDLNs-中TCF-1+PD-1-CD8+ T细胞及CD11c+细胞密度高于非应答者。值得注意的是，TDLNs-中较高比例的TCF-1+PD-1-CD8+ T细胞与PFS延长相关，而广泛清扫TDLNs-会削弱这一获益。
> 
> 研究结论：过度清除TDLNs-会削弱复发性BTC患者的免疫治疗效果。优先切除TDLNs+、同时保留TDLNs-的选择性淋巴结清扫策略，可能为术后接受免疫治疗的患者带来更优临床结局。

### 第二部分 AI 大师评价

本研究基于多中心真实世界数据，系统评估了复发性胆道癌患者中非转移性肿瘤引流淋巴结清扫范围对免疫治疗疗效的影响。研究发现，过度清扫TDLNs-显著缩短无进展生存期，并与免疫效应细胞减少及免疫衰竭表型相关。该结果揭示了免疫微环境层面的手术与免疫治疗交互机制，提示临床上应优化淋巴结切除策略以提升免疫治疗获益。尽管研究样本量有限且为回顾性设计，但为胆道癌术后治疗的精准化提供了重要依据。

---

## 4. MAPK通路突变在IDH1突变抑制剂耐药的胆管癌中出现并削弱干扰素反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460204)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41460204
**DOI：** 10.1158/1078-0432.CCR-25-3284

### 第一部分 原文与翻译

**英文原标题：** MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon Response.

> **英文摘要：**
> BACKGROUND: Mutant IDH1 (mIDH1) defines a therapeutically-targetable subtype of intrahepatic cholangiocarcinoma (ICC), with the mIDH1 inhibitor ivosidenib approved for advanced disease. A subset of patients experiences prolonged disease stabilization, although the molecular basis for eventual progression remains poorly defined.
> 
> EXPERIMENTAL DESIGN: We performed molecular profiling of matched baseline and post-progression circulating tumor DNA (ctDNA) samples from patients with mIDH1 ICC enrolled in the ClarIDHy phase III trial. Functional studies were conducted to characterize candidate resistance mechanisms.
> 
> RESULTS: Longitudinal ctDNA analysis of 18 patients treated with ivosidenib for >6 months revealed emergent genomic alterations in multiple cases. Acquired mutations in MAPK-pathway genes (KRAS, NRAS, MAP2K1, NF1) were identified in five cases, with instances of concurrent alterations and/or high variant allele fractions (VAF). Additional candidate resistance events included a secondary IDH1 mutation and a hotspot IDH2 mutation, detected at low VAF in the same patient. Functional studies demonstrated that these IDH mutations conferred sustained 2-hydroxyglutarate (2HG) production and ivosidenib resistance, whereas MAPK activation blunted gene expression induced by ivosidenib plus interferon-γ, a key therapeutic output of mIDH1 inhibition. In parallel, baseline ctDNA profiling of 81 patients linked ARID1A mutations and elevated mIDH1 VAF to reduced clinical benefit.
> 
> CONCLUSIONS: MAPK-pathway alterations represent a recurrent mechanism of resistance to mIDH1 inhibition in ICC, while emergent IDH1/IDH2 mutations appear infrequent. Functional data suggest that MAPK-mediated resistance may involve impaired IFN signaling. These results support MAPK-directed combination strategies and highlight the utility of ctDNA profiling to identify predictive and resistance biomarkers in mIDH1-driven ICC.

> **中文摘要：**
> 背景：IDH1突变（mIDH1）定义了一种可靶向治疗的肝内胆管癌（ICC）亚型，mIDH1抑制剂ivosidenib已被批准用于晚期疾病。部分患者可获得长期疾病稳定，但其最终进展的分子机制尚不明确。
> 
> 实验设计：本研究对入组ClarIDHy III期临床试验的mIDH1 ICC患者的基线及疾病进展后的血浆循环肿瘤DNA（ctDNA）样本进行分子特征分析。并开展功能研究以阐明潜在的耐药机制。
> 
> 结果：对18例接受ivosidenib治疗超过6个月的患者进行纵向ctDNA分析，显示多例出现新的基因组改变。在5例中检测到MAPK通路基因（KRAS、NRAS、MAP2K1、NF1）的获得性突变，并观察到同时存在多种改变和/或较高的变异等位基因频率（VAF）。此外，还发现额外的耐药事件，包括同一患者中检测到低VAF的次级IDH1突变和热点IDH2突变。功能研究表明，这些IDH突变可维持2-羟基戊二酸（2HG）持续生成并导致ivosidenib耐药，而MAPK通路激活则削弱了ivosidenib联合干扰素-γ诱导的基因表达——这一过程是mIDH1抑制治疗的关键作用机制。与此同时，对81例患者的基线ctDNA分析发现，ARID1A突变及较高的mIDH1 VAF与较低的临床获益相关。
> 
> 结论：MAPK通路改变是ICC中mIDH1抑制耐药的常见机制，而新的IDH1/IDH2突变相对罕见。功能数据提示，MAPK介导的耐药可能与干扰素信号受损有关。这些结果支持针对MAPK的联合治疗策略，并强调ctDNA分析在识别mIDH1驱动ICC预测和耐药生物标志物方面的潜在价值。

### 第二部分 AI 大师评价

该研究针对IDH1突变型肝内胆管癌患者在ivosidenib治疗后进展的分子机制进行了系统性探索。通过纵向ctDNA分析和功能实验，研究发现MAPK通路突变是主要的获得性耐药机制，并证实这些突变可削弱干扰素信号通路的治疗应答。该研究突出了ctDNA在监测耐药演变和筛选生物标志物中的应用价值，提示MAPK信号抑制可能成为未来联合治疗的方向。研究样本量有限，后续仍需扩大验证以确认这些发现的临床意义。

---

## 5. Erdafitinib治疗伴FGFR基因改变的晚期或转移性胆管癌患者的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460200)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41460200
**DOI：** 10.1158/1078-0432.CCR-25-2264

### 第一部分 原文与翻译

**英文原标题：** Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma.

> **英文摘要：**
> PURPOSE: Up to 20% of patients with cholangiocarcinoma (CCA) harbor FGFR gene aberrations; erdafitinib is approved for pretreated, locally advanced/metastatic urothelial carcinoma with susceptible FGFR3 alterations. The present study evaluated the efficacy and safety of erdafitinib using a pooled analysis of patients with CCA from the RAGNAR and LUC2001 studies.
> 
> PATIENTS AND METHODS: In RAGNAR (phase 2, global, tumor-agnostic study) and LUC2001 (an open-label, multicenter, phase 2a study in Asian patients), patients with advanced solid tumors after ≥1 prior lines of therapy received once-daily oral erdafitinib (8 mg/day with an option for pharmacodynamically guided up-titration to 9 mg). Patients were pooled for efficacy (objective response rate [ORR] per a blinded independent review committee, duration of response [DOR], progression-free survival [PFS], overall survival [OS]) and safety analyses.
> 
> RESULTS: At a median efficacy follow-up of 14.7 months in 78 erdafitinib-treated patients (RAGNAR: n=66; LUC2001: n=12), ORR was 55% (95% CI: 43.4-66.4). Median time to response was 1.7 months; median DOR, PFS, and OS were 6.9 (95% CI: 4.37-8.61), 8.5 (95% CI: 6.83 -9.72), and 18.1 (95% CI: 13.40-24.28) months, respectively. Most common treatment-emergent adverse events (TEAEs) were hyperphosphatemia (83%), stomatitis (72%), diarrhea (68%), dry mouth (51%), palmar-plantar erythrodysesthesia (51%); 42% had serious TEAEs, and 12% had TEAEs leading to treatment discontinuation.
> 
> CONCLUSIONS: Pooled analyses confirm the robust efficacy of erdafitinib in a diverse population of pretreated patients with advanced/metastatic CCA harboring prespecified FGFR alterations. These findings are consistent with previously observed efficacy of FGFR-targeted agents in patients with CCA.

> **中文摘要：**
> 研究目的：多达20%的胆管癌（CCA）患者存在FGFR基因异常；Erdafitinib已获批用于既往接受治疗的、局部晚期或转移性并具有可靶向FGFR3改变的尿路上皮癌。本研究通过汇总RAGNAR和LUC2001研究中CCA患者的数据，评估Erdafitinib的疗效和安全性。
> 
> 患者与方法：RAGNAR是一项全球性、肿瘤类型无关、Ⅱ期研究；LUC2001是一项针对亚洲患者的开放性、多中心、Ⅱa期研究。既往接受过≥1线治疗的晚期实体肿瘤患者口服Erdafitinib，每日一次（8 mg/天，可根据药效学指导加至9 mg）。患者被合并用于疗效（客观缓解率[ORR]由盲法独立评审委员会评定、缓解持续时间[DOR]、无进展生存期[PFS]、总生存期[OS]）及安全性分析。
> 
> 结果：在78例接受Erdafitinib治疗的患者（RAGNAR: n=66；LUC2001: n=12）中，中位疗效随访为14.7个月，客观缓解率为55%（95% CI: 43.4–66.4）。中位起效时间为1.7个月；中位DOR、PFS和OS分别为6.9个月（95% CI: 4.37–8.61）、8.5个月（95% CI: 6.83–9.72）和18.1个月（95% CI: 13.40–24.28）。最常见的治疗出现不良事件（TEAEs）包括高磷血症（83%）、口腔炎（72%）、腹泻（68%）、口干（51%）、手足红斑感觉异常（51%）；42%的患者出现严重TEAEs，12%的患者因TEAEs停药。
> 
> 结论：综合分析证实Erdafitinib在伴有特定FGFR改变的、既往接受治疗的晚期/转移性CCA患者中具有显著疗效。这些结果与以往针对FGFR靶向药物在CCA患者中的疗效观察一致。

### 第二部分 AI 大师评价

该研究通过汇总RAGNAR与LUC2001两项研究数据，系统评估了Erdafitinib在伴FGFR基因改变的晚期或转移性胆管癌中的疗效与安全性。结果显示该药物具有较高的客观缓解率与持续的生存获益，主要不良事件可控。研究创新性在于运用肿瘤类型无关的设计验证FGFR靶向治疗在胆管癌中的应用。局限性在于样本量较小及缺乏对照组验证，仍需进一步随机对照研究加以确认。

---

## 6. 不同的分子特征描绘了IDH突变型低级别星形细胞瘤和少突胶质细胞瘤的自发生长速率。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460180)
**期刊：** Neuro-oncology
**PMID：** 41460180
**DOI：** 10.1093/neuonc/noaf296

### 第一部分 原文与翻译

**英文原标题：** Distinct molecular profiles characterize the spontaneous growth rate of IDHmt low-grade astrocytomas and oligodendrogliomas.

> **英文摘要：**
> BACKGROUND: The life expectancy of patients with diffuse IDH-mutant low-grade gliomas (IDHmt LGG) ranges from 5 to over 20 years. Tumor behavior, including spontaneous growth rate, varies even within homogeneously classified subtypes of oligodendroglioma and astrocytoma. Risk-adjusted treatment strategies are needed to avoid therapy-related toxicities, without compromising outcome. The spontaneous tumor volume growth rate (TVGR) serves as a prognostic marker and predicts response to therapy. Accurate prediction of TVGR through biomarkers would enable an improved evidence-based risk management.
> 
> PATIENTS & METHODS: A cohort of 77 patients treated in Montpellier, France, for IDHmt LGG grade II (WHO 2016) (29 oligodendrogliomas, 48 astrocytomas) was constituted (age >18 years; MRI scans, frozen tumor tissue). The DNA methylome (Illumina, EPIC array) and transcriptome (RNAseq) were established. TVGR was determined based on serial MRIs collected over the "watch & wait" period before first treatment beyond surgery. Transcriptomic and methylome data were analyzed for signatures associated with TVGR using rank-rank regression followed by preranked gene set enrichment analysis.
> 
> RESULTS: : The median TVGR was lower in IDHmt codeleted compared to non-codeleted LGG, (0.241 year-1 range 0.082-0.366 vs 0.424 year-1 range 0.264-0.609, p < 0.001). In codeleted IDHmt LGG, TVGR was associated with upregulated gene signatures for neuronal systems, synaptic activity, and activation of repressed or poised signatures of neural progenitor cells; while the TVGR in non-codeleted IDHmt LGG was dominanted by upregulated proliferation-related signatures, including DNA replication and repair.
> 
> CONCLUSION: Spontaneous TVGR of codeleted and non-codeleted IDHmt LGG involve distinct biological processes, suggesting possible differences in response to therapies.

> **中文摘要：**
> 背景：弥漫性IDH突变型低级别胶质瘤（IDHmt LGG）患者的预期寿命从5年至超过20年不等。即使在组织学上同质分类的少突胶质细胞瘤和星形细胞瘤亚型中，肿瘤行为（包括自发生长速率）也存在差异。需要基于风险调整的治疗策略，以避免治疗相关毒性，同时不影响疗效。肿瘤体积自发生长速率（TVGR）可作为预后标志物并预测治疗反应。通过生物标志物准确预测TVGR将有助于基于证据的风险管理。
> 
> 患者与方法：在法国蒙彼利埃，纳入77例IDHmt LGG II级（WHO 2016分类）的患者（包括29例少突胶质细胞瘤与48例星形细胞瘤，年龄>18岁；采集MRI影像与冻存肿瘤组织）。进行了DNA甲基化组（Illumina EPIC芯片）和转录组（RNA测序）分析。TVGR通过术后首次治疗前“观察等待”期间收集的连续MRI计算得出。应用秩-秩回归及预排序基因集富集分析，评估与TVGR相关的转录组与甲基化特征。
> 
> 结果：与非共缺失LGG相比，共缺失IDHmt LGG的中位TVGR更低（0.241 年⁻¹，范围 0.082–0.366 vs 0.424 年⁻¹，范围 0.264–0.609，p < 0.001）。在共缺失IDHmt LGG中，TVGR与神经系统、突触活动及被抑制或处于潜能状态的神经祖细胞标志的上调基因特征相关；而在非共缺失IDHmt LGG中，TVGR主要与细胞增殖相关特征的上调相关，包括DNA复制与修复过程。
> 
> 结论：共缺失与非共缺失的IDHmt LGG的自发TVGR涉及不同的生物学过程，这提示其对治疗反应可能存在差异。

### 第二部分 AI 大师评价

该研究旨在揭示IDH突变型低级别胶质瘤在不同分子亚型间的自发生长速率差异及其生物学基础。作者通过DNA甲基化组与转录组数据整合分析，发现共缺失型与非共缺失型肿瘤呈现截然不同的分子特征，前者偏向神经元活性与神经前体细胞通路，后者则富含增殖相关信号。研究在强调精准分子分层与预测生长动力学方面具有创新价值，但样本量及单中心设计可能限制其普适性。整体上，该工作为未来基于分子特征的风险评估与治疗策略优化提供了重要线索。

---

## 7. 在乳腺癌进展后持续使用 CDK4/6 抑制剂并联合 CDK2 抑制剂的治疗获益。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41459763)
**期刊：** eLife
**PMID：** 41459763
**DOI：** 10.7554/eLife.104545

### 第一部分 原文与翻译

**英文原标题：** Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer.

> **英文摘要：**
> CDK4/6 inhibitors (CDK4/6i) with endocrine therapy are standard for hormone receptor-positive (HR) metastatic breast cancer. However, most patients eventually develop resistance and discontinue treatment, and there is currently no consensus on effective second-line strategies. Using preclinical HR human breast cancer models with acquired resistance to CDK4/6i, we demonstrate that maintaining CDK4/6i therapy, either alone or combined with CDK2 inhibitors (CDK2i), slows the growth of resistant tumors by prolonging G1 progression. Mechanistically, sustained CDK4/6 blockade in drug-resistant cells reduces E2F transcription and delays G1/S via a noncanonical, posttranslational regulation of retinoblastoma protein (Rb). Durable suppression of both CDK2 activity and growth of drug-resistant cells requires co-administration of CDK2i with CDK4/6i. Moreover, cyclin E overexpression drives resistance to the combination of CDK4/6i and CDK2i. These findings elucidate how continued CDK4/6 blockade constrains resistant tumors and support clinical strategies that maintain CDK4/6i while selectively incorporating CDK2i to overcome resistance.

> **中文摘要：**
> 将 CDK4/6 抑制剂（CDK4/6i）与内分泌治疗联合使用是激素受体阳性（HR）转移性乳腺癌的标准治疗方案。然而，大多数患者最终会产生耐药性并停止治疗，目前尚无公认的有效二线治疗策略。利用获得 CDK4/6i 耐药性的临床前 HR 阳性人乳腺癌模型，我们证明维持 CDK4/6i 治疗，无论是单独使用还是与 CDK2 抑制剂（CDK2i）联合使用，都可以通过延长 G1 期进程来减缓耐药性肿瘤的生长。从机制上看，在耐药细胞中持续阻断 CDK4/6 可通过非经典的视网膜母细胞瘤蛋白（Rb）翻译后调控途径降低 E2F 的转录并延迟 G1/S 转换。稳定抑制 CDK2 活性及耐药细胞的生长需要 CDK2i 与 CDK4/6i 的联合应用。此外，Cyclin E 的过表达会驱动对 CDK4/6i 与 CDK2i 联合治疗的耐药性。这些发现阐明了持续的 CDK4/6 阻断如何限制耐药性肿瘤，并为在维持 CDK4/6i 的同时选择性联合 CDK2i 以克服耐药提供了临床策略依据。

### 第二部分 AI 大师评价

该研究针对 CDK4/6 抑制剂治疗乳腺癌后出现耐药的难题，提出了在疾病进展后继续维持 CDK4/6 抑制剂并联合 CDK2 抑制剂的策略。作者通过临床前模型系统性探讨了这种联合方案对肿瘤增殖周期与分子机制的影响，揭示了 Rb 蛋白非经典调控及 Cyclin E 过表达在耐药性中的作用。结果表明持续 CDK4/6 阻断仍具生物学抑制价值，并可通过联合 CDK2 抑制进一步强化疗效。该研究为抗耐药靶向策略提供了新的理论依据，但其转化至临床仍需进一步验证。

---

## 8. ADAMTS9-AS2通过抑制干性和诱导铁死亡干扰去势抵抗性前列腺癌的多西他赛耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41457913)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41457913
**DOI：** 10.1002/advs.202520838

### 第一部分 原文与翻译

**英文原标题：** ADAMTS9-AS2 Disrupts Docetaxel-Resistance in Castration-Resistant Prostate Cancer via Stemness Suppression and Ferroptosis Induction.

> **英文摘要：**
> Castration-resistant prostate cancer (CRPC) chemotherapy resistance remained a significant clinical challenge. Prostate tumor stem cells (PCSCs) played a crucial role in chemotherapy resistance, but the underlying mechanisms were not fully understood. This study investigated how ADAMTS9-AS2 reduced chemotherapy resistance in CRPC through a dual mechanism and explored the potential of polymeric materials targeting PCSCs and enhancing chemotherapy sensitivity. Key regulatory molecules of PCSCs were identified through mRNAsi-based multi-center patient cohorts. The effect of ADAMTS9-AS2 on reducing docetaxel resistance in CRPC was assessed, and its mechanisms were further explored using in vitro and in vivo experiments. Finally, polymeric materials containing TGF-β inhibitor, ferroptosis inducer, and miR-182-5p inhibitor were used to target PCSCs to improve chemotherapy sensitivity. ADAMTS9-AS2 reduced CRPC chemotherapy resistance through dual mechanisms: (1) regulating FOXF2/TGF-β2 axis to suppress PCSCs stemness; (2) encoding a short peptide that competitively retained more SLC7A11 in the cytoplasm than on the cytomembrane, thus promoting ferroptosis. Furthermore, polymeric materials targeting PCSCs significantly enhanced docetaxel sensitivity and inhibited tumor progression. ADAMTS9-AS2 delayed docetaxel resistance by suppressing CRPC stemness and inducing ferroptosis. The use of polymeric materials targeting PCSCs offered a novel strategy to overcome CRPC chemotherapy resistance.

> **中文摘要：**
> 去势抵抗性前列腺癌（CRPC）的化疗耐药性仍然是重大临床挑战。前列腺肿瘤干细胞（PCSCs）在化疗耐药中发挥关键作用，但其潜在机制尚未完全阐明。本研究探讨了ADAMTS9-AS2如何通过双重机制降低CRPC的化疗耐药性，并评估了靶向PCSCs的聚合物材料在增强化疗敏感性方面的潜力。研究通过基于mRNAsi的多中心患者队列鉴定了PCSCs的关键调控分子。进一步评估了ADAMTS9-AS2在降低CRPC多西他赛耐药性方面的作用，并通过体内外实验探索其作用机制。最后，研究利用含有TGF-β抑制剂、铁死亡诱导剂及miR-182-5p抑制剂的聚合物材料靶向PCSCs，以提高化疗敏感性。ADAMTS9-AS2通过双重机制降低CRPC化疗耐药性：（1）调控FOXF2/TGF-β2轴以抑制PCSCs的干性；（2）编码一条短肽，使其在细胞质中竞争性保留更多SLC7A11而非定位于细胞膜上，从而促进铁死亡。此外，靶向PCSCs的聚合物材料显著增强了多西他赛敏感性并抑制了肿瘤进展。ADAMTS9-AS2通过抑制CRPC干性及诱导铁死亡延缓了多西他赛耐药性。靶向PCSCs的聚合物材料的使用为克服CRPC化疗耐药提供了一种新策略。

### 第二部分 AI 大师评价

该研究围绕去势抵抗性前列腺癌化疗耐药问题，揭示了长链非编码RNA ADAMTS9-AS2通过抑制肿瘤干性与诱导铁死亡双重机制降低多西他赛耐药性。作者结合体内外实验与多中心mRNAsi数据，系统验证了FOXF2/TGF-β2通路及SLC7A11定位调控在耐药逆转中的作用，并设计了可同时递送TGF-β抑制剂、铁死亡诱导剂及miR-182-5p抑制剂的聚合物复合材料以强化疗效。该研究为靶向前列腺癌干细胞、提升化疗敏感性提供了创新性的纳米材料策略，但仍需更多临床研究验证其安全性与可转化潜力。

---

## 9. 靶向DAP5破坏调节性T细胞中替代型翻译起始模式并增强抗肿瘤免疫力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41457459)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41457459
**DOI：** 10.1002/advs.202520625

### 第一部分 原文与翻译

**英文原标题：** Targeting DAP5 Disrupts Alternate Mode of Translational Initiation in Tregs and Potentiates Antitumor Immunity.

> **英文摘要：**
> Regulatory T cells (Tregs) can thrive in the harsh tumor microenvironment (TME) to dampen antitumor immunity. Chronic stresses within TME compromise canonical cap-dependent translation (CDT), which compromises effector T cell function but not Treg persistence. Death-associated protein 5 (DAP5/eIF4G2), a non-classical translational scaffold, has been reported to support human Treg differentiation in vitro, but its functions in thymic Treg development, peripheral Treg homeostasis, and tumor-infiltrating Treg (ti-Treg) fitness remain unclear. Here, it is shown that DAP5 expression positively correlates with ti-Treg frequencies in both colorectal cancer patients and murine subcutaneous tumors. Mice with homozygous Dap5 deletion in Tregs has intact thymic and peripheral Treg development but spontaneously developed typical scurfy symptoms. Haploinsufficiency of Dap5 in Tregs preserves peripheral immune homeostasis while suppressing tumor growth, with enhanced CD8 T cell infiltration and effector function. Mechanistically, Dap5 mediates alternate mode of translation of transcripts encoding CD25 and MCL-1 in Tregs, thereby sustaining Treg lineage stability and survival in the stressful TME. Overall, Tregs rely on DAP5-driven alternate translation to maintain peripheral homeostasis and acquired fitness within the TME. Selective disruption of this pathway impairs ti-Tregs while sparing systemic tolerance, offering a potential therapeutic strategy to enhance anti-tumor immunity.

> **中文摘要：**
> 调节性T细胞（Tregs）能够在恶劣的肿瘤微环境（TME）中存活并削弱抗肿瘤免疫。TME内的慢性应激会损害经典的依赖帽结构的翻译（CDT），从而削弱效应性T细胞功能，但不会影响Treg的持续存在。死亡相关蛋白5（DAP5/eIF4G2）是一种非经典的翻译支架，已被报道在体外支持人Treg的分化，但其在胸腺Treg发育、外周Treg稳态及肿瘤浸润性Treg（ti-Treg）适应性中的作用尚不清楚。本研究显示，在结直肠癌患者和小鼠皮下肿瘤中，DAP5的表达与ti-Treg的比例呈正相关。在Treg中纯合缺失Dap5的小鼠具有完整的胸腺和外周Treg发育，但自发出现典型的“scurfy”症状。Treg中Dap5单倍剂量不足可维持外周免疫稳态，同时抑制肿瘤生长，并增强CD8 T细胞的浸润及效应功能。在机制上，Dap5介导Treg中CD25和MCL-1编码转录本的替代翻译模式，从而在应激的TME中维持Treg谱系稳定性和生存性。总体而言，Tregs依赖DAP5驱动的替代翻译以维持外周稳态及其在TME中的适应性。选择性破坏这一途径可损伤ti-Tregs而不影响系统耐受性，为增强抗肿瘤免疫提供潜在治疗策略。

### 第二部分 AI 大师评价

该研究旨在揭示DAP5在调节性T细胞翻译调控及肿瘤免疫中的关键作用。作者通过遗传修饰小鼠模型证明，DAP5缺失选择性削弱肿瘤浸润性Treg功能，而不影响整体免疫耐受。分子机制研究显示，DAP5介导CD25与MCL-1的非经典翻译维持Treg生存与稳定。该发现为开发靶向DAP5、提高抗肿瘤免疫的新策略提供了理论依据，但仍需验证其在不同肿瘤类型及临床人群中的适用性。

---

## 10. γδ T细胞受体以脂质非依赖方式识别CD1d的机制研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41457154)
**期刊：** Nature communications
**PMID：** 41457154
**DOI：** 10.1038/s41467-025-67653-0

### 第一部分 原文与翻译

**英文原标题：** γδ T cell receptor recognition of CD1d in a lipid-independent manner.

> **英文摘要：**
> The monomorphic antigen-presenting molecule CD1d presents lipid antigens to both αβ and γδ T cells. While type I natural killer T cells (NKT) display exquisite specificity for CD1d presenting α-galactosylceramide (α-GalCer), the extent of lipid specificity exhibited by CD1d-restricted γδ T cells remains unclear. Here, we demonstrate that human γδ T cell receptors (TCRs) can recognise CD1d in either a lipid-dependent or lipid-independent manner with weak to moderate affinity. Using small-angle X-Ray scattering, we find that γδ TCR-CD1d binding modality is conserved across distinct CD1d-restricted TCRs. In functional assays, CD1d γδ TCR affinity was a poor predictor of γδ T cell line activation. Moreover, CD1d presenting endogenous lipids was sufficient to stimulate T cell activation and induce γδ TCR-CD3 clustering and phosphorylation in a dose-dependent manner. Elongation of the γδ TCR-CD3 complex by the inclusion of the Cγ2 and Cγ3 -encoded constant domains perturbed cellular activation whilst maintaining the ability to form functional γδ TCR clusters. The crystal structure of a Vδ1 γδ TCR-CD1d complex showed that the γδ TCR sat atop of the CD1d antigen-binding cleft but made no contacts with the presented lipid antigen. These findings provide a molecular basis for lipid-independent CD1d recognition by γδ TCRs.

> **中文摘要：**
> 单态抗原呈递分子CD1d可向αβ T细胞与γδ T细胞呈递脂质抗原。虽然I型自然杀伤T细胞（NKT）对呈递α-半乳糖神经酰胺（α-GalCer）的CD1d表现出极高的特异性，但CD1d限制性γδ T细胞所表现的脂质特异性范围仍不清楚。在本研究中，我们证明人类γδ T细胞受体（TCR）可通过脂质依赖或脂质非依赖的方式识别CD1d，并具有低至中等亲和力。利用小角X射线散射，我们发现γδ TCR与CD1d的结合模式在不同CD1d限制性TCR中具有保守性。在功能实验中，CD1d与γδ TCR的亲和力对预测γδ T细胞系的活化效果较差。此外，仅由CD1d呈递的内源性脂质即足以诱导T细胞活化，并以剂量依赖方式促进γδ TCR-CD3的聚集与磷酸化。将Cγ2与Cγ3编码的恒定结构域引入γδ TCR-CD3复合物使其延长，干扰了细胞活化，但仍保留形成功能性γδ TCR簇的能力。Vδ1型γδ TCR-CD1d复合物的晶体结构显示，γδ TCR位于CD1d抗原结合槽上方，但并未与所呈递的脂质抗原发生直接接触。这些发现为γδ TCR脂质非依赖性识别CD1d提供了分子基础。

### 第二部分 AI 大师评价

该研究阐明了人类γδ T细胞受体对CD1d分子的识别机制，发现其既可依赖脂质，也可非依赖脂质，与传统NKT细胞的高脂质特异性形成对比。通过结构和功能学分析，研究揭示了γδ TCR-CD1d结合模式的保守性及其与T细胞活化之间的复杂关系。晶体学结果突出了γδ TCR在不接触脂质抗原情况下识别CD1d的独特方式。该工作为理解γδ T细胞的天然免疫识别机制提供了新见解，但对其生理意义及调控机制仍需进一步研究。

---

## 11. Dysadherin/YAP轴促进肝癌的干性可塑性与免疫逃逸。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41457101)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41457101
**DOI：** 10.1038/s41392-025-02520-4

### 第一部分 原文与翻译

**英文原标题：** Dysadherin/YAP axis fuels stem plasticity and immune escape in liver cancer.

> **英文摘要：**
> Hepatocellular carcinoma (HCC) is an aggressive malignancy that is often refractory to chemotherapy and immune checkpoint inhibitors. This therapeutic resistance is driven in part by the persistence of cancer stem-like cells (CSCs) and the development of an immune-cold tumor microenvironment. However, the upstream regulators that coordinate these malignant features remain poorly defined. In this study, we identified dysadherin as a novel upstream activator of YAP that promotes both CSC plasticity and immune evasion through the FAK/YAP/TEAD2 signaling axis. Using single-cell transcriptomic analysis, in vitro assays, and multiple in vivo models including a humanized immune mouse system, we showed that dysadherin enhances the expression of pluripotency genes, such as OCT4 and upregulates PD-L1. These changes support stem-like tumor behavior and contribute to T-cell exclusion, fostering an immunosuppressive niche. Notably, genetic knockdown or peptide-based pharmacologic inhibition of dysadherin effectively restored antitumor immune activation, suppressed metastasis and improved therapeutic responsiveness. Our findings reveal a mechanistic link between dysadherin-mediated cell adhesion signaling and the transcriptional regulation of both stemness and immune escape. Collectively, these findings establish the dysadherin/YAP axis as a key driver of HCC progression and resistance, and highlight it as a compelling therapeutic target that could overcome treatment failure in advanced liver cancer.

> **中文摘要：**
> 肝细胞癌（HCC）是一种具有高度侵袭性的恶性肿瘤，常对化疗和免疫检查点抑制剂表现出耐药性。这种治疗抵抗部分由癌症干样细胞（CSC）的持续存在以及免疫冷却型肿瘤微环境的形成所驱动。然而，协调这些恶性特征的上游调控因子仍不清楚。在本研究中，我们鉴定出dysadherin是YAP的新型上游激活因子，通过FAK/YAP/TEAD2信号轴共同促进CSC的可塑性和免疫逃逸。通过单细胞转录组分析、体外实验以及包括人源化免疫小鼠系统在内的多种体内模型，我们发现dysadherin可增强多能性基因如OCT4的表达，并上调PD-L1。这些变化支持了肿瘤的干样行为，并促使T细胞排斥，从而形成免疫抑制性生态位。值得注意的是，遗传学敲低或基于肽的药理性抑制dysadherin能够有效恢复抗肿瘤免疫活性，抑制转移并改善治疗反应性。我们的研究揭示了dysadherin介导的细胞黏附信号与干性及免疫逃逸转录调控之间的机制联系。总体而言，这些发现确立了dysadherin/YAP轴作为肝细胞癌进展和耐药的关键驱动因素，并凸显其作为一种有潜力克服晚期肝癌治疗失败的治疗靶点的重要性。

### 第二部分 AI 大师评价

该研究围绕肝细胞癌的耐药与免疫逃逸机制展开，通过多层次的实验验证发现dysadherin/YAP轴在维持肿瘤干性和免疫抑制中起关键作用。作者结合单细胞转录组学、体外与体内模型分析，系统揭示了该信号通路在HCC进展中的功能与分子机制。研究亮点在于将细胞黏附信号与干性及免疫逃逸调控相联系，并提出dysadherin作为潜在治疗靶点的应用前景。其创新性显著，但仍需进一步临床验证其可行性和药物开发潜力。

---

## 12. BATF2 是一种谷氨酰胺响应型肿瘤抑制因子，参与Ⅰ型干扰素依赖的抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41457098)
**期刊：** Nature communications
**PMID：** 41457098
**DOI：** 10.1038/s41467-025-68027-2

### 第一部分 原文与翻译

**英文原标题：** BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent anti-tumour immunity.

> **英文摘要：**
> Recent evidence highlights the significance of a new type of tumour suppressors, which are not frequently mutated but inhibited by metabolic cues in cancers. Here, we identify BATF2 as a tumour suppressor whose expression is epigenetically silenced by glutamine in Head and Neck Squamous Cell Carcinomas (HNSCC). BATF2 correlates with type-I interferon and Th1 signatures in human HNSCC, with correlation coefficients even stronger than those of the positive control, STING. The phosphorylation of BATF2 at serine 227 promotes the oligomerization of STING. BATF2 deficiency or high glutamine levels result in higher oxygen consumption rates and metabolic profiles unfavorable for type-I interferon production. An isocaloric glutamine-rich diet abolishes STING-mediated effector cell expansion in tumours, weakening STING agonist-induced tumour control. Cancer cell-specific BATF2 expression promotes an Id2-centered T-cell effector signature, reduces T-cell exhaustion, and triggers spontaneous HNSCC rejection in a type-I interferon-dependent fashion. Utilizing syngeneic subcutaneous, orthotopic, and 24-week-long cigarette smoke carcinogen-induced HNSCC models, we demonstrate that host Batf2 deficiency results in increased infiltration of CD206 myeloid cells and reduced effector CD8 T-cells, accelerating the initiation of cancers. Overall, we reveal a tumour suppressor BATF2 whose loss is mediated by unique metabolic cues in the TME and drives cancer immune escape.

> **中文摘要：**
> 最新证据强调了一类新的肿瘤抑制因子的意义，这类因子并非频繁发生突变，而是被肿瘤中的代谢信号所抑制。在本研究中，我们发现 BATF2 是一种肿瘤抑制因子，其表达在头颈鳞状细胞癌（HNSCC）中受到谷氨酰胺的表观遗传沉默调控。BATF2 在人类 HNSCC 中与Ⅰ型干扰素和 Th1 表型呈正相关，其相关系数甚至强于阳性对照 STING。BATF2 在丝氨酸 227 位点的磷酸化可促进 STING 的寡聚化。BATF2 缺失或高水平谷氨酰胺会导致较高的氧耗率及对Ⅰ型干扰素产生不利的代谢模式。等热量的高谷氨酰胺饮食可抑制 STING 介导的效应细胞扩增，从而削弱由 STING 激动剂诱导的肿瘤控制。肿瘤细胞特异性的 BATF2 表达可促进以 Id2 为中心的 T 细胞效应特征，减少 T 细胞衰竭，并以Ⅰ型干扰素依赖的方式触发 HNSCC 的自发性清除。通过使用同系异种皮下、原位及持续 24 周的烟草致癌物诱导的 HNSCC 模型，我们证明宿主 Batf2 缺失会导致 CD206 髓系细胞浸润增加和效应型 CD8 T 细胞减少，从而加速癌症的发生。总体而言，我们揭示了肿瘤微环境中由独特代谢信号介导丧失的肿瘤抑制因子 BATF2，其缺失驱动了癌症的免疫逃逸。

### 第二部分 AI 大师评价

本研究揭示了 BATF2 作为一种受谷氨酰胺代谢调控的肿瘤抑制因子，在Ⅰ型干扰素依赖的抗肿瘤免疫中发挥关键作用。研究利用多种 HNSCC 模型，系统分析了 BATF2 缺失与免疫浸润、代谢重编程及肿瘤发生之间的因果关系。其发现将代谢调控与免疫逃逸机制紧密关联，提出了代谢-免疫交叉的新概念。尽管临床转化仍需进一步验证，但本研究为代谢干预联合免疫治疗提供了新的理论依据与潜在靶点。

---

## 13. 血浆蛋白质谱分析可预测具有非特异性症状患者的癌症风险

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41457066)
**期刊：** Nature communications
**PMID：** 41457066
**DOI：** 10.1038/s41467-025-67688-3

### 第一部分 原文与翻译

**英文原标题：** Plasma protein profiling predicts cancer in patients with non-specific symptoms.

> **英文摘要：**
> Cancer detection is challenging, especially in patients with diffuse symptoms that overlap with non-malignant conditions. Here we show that plasma protein profiling can identify cancer among patients with non-specific symptoms. Using proximity extension assay-based proteomics of 1463 plasma proteins from 456 patients presenting with non-specific symptoms sampled prior to cancer diagnostic work-up and diagnosis, we identify 29 proteins associated with new cancer diagnoses. We develop a model able to stratify 160 cancer cases and 296 non-cancer cases with an area under the curve of 0.80, maintaining performance (0.82) in an independent replication cohort of 238 patients. The model also distinguishes cancer from autoimmune, inflammatory and infectious diseases. Designed as a triage tool, our model based on a blood test could help prioritize patients at higher cancer risk for rapid and highly sensitive diagnostic modalities such as positron emission tomography-computed tomography. These findings emphasize the potential of blood proteome profiling to support timely diagnosis and transform clinical medicine.

> **中文摘要：**
> 癌症的检测颇具挑战性，尤其在表现为弥漫性、与非恶性疾病症状重叠的患者中更为困难。本研究表明，血浆蛋白质谱分析可用于识别具有非特异性症状的患者中是否存在癌症。研究人员在癌症诊断工作启动及确诊之前，采用基于近邻延伸分析（proximity extension assay）的蛋白质组学技术，对456名具有非特异性症状患者的血浆样本进行了分析，测定了1463种血浆蛋白，并鉴定出29种与新发癌症诊断相关的蛋白。研究者进一步建立了一个模型，可将160例癌症患者与296例非癌患者进行分层区分，其曲线下面积（AUC）为0.80；在一个包含238名患者的独立验证队列中，该模型的性能保持稳定（AUC为0.82）。此外，该模型还能区分癌症与自身免疫性、炎症性及感染性疾病。本模型被设计为一种分诊工具，基于血液检测的筛查可帮助优先识别癌症高风险患者，从而快速引导至高敏感度的诊断手段，如正电子发射断层-计算机断层扫描（PET-CT）。这些结果强调了血液蛋白质组学在支持及时诊断与推动临床医学变革方面的潜力。

### 第二部分 AI 大师评价

该研究旨在通过血浆蛋白质组学探索快速鉴别非特异性症状患者中潜在癌症的方法。研究利用基于近邻延伸分析的高通量蛋白检测，鉴定出29种与癌症新诊断显著相关的蛋白，并构建了可稳定区分癌与非癌患者的预测模型。模型表现出良好的灵敏度与独立验证性能，并可区分多种非肿瘤性疾病。这一成果在癌症早期分诊领域具有创新性，为血液学无创检测的临床应用提供了新思路，但仍需在更大人群和前瞻性环境中验证模型的泛化能力。

---

速递结束，祝您工作愉快！